Skip to main content

Table 1

From: O414 48-week data from Study AVX-201 – a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance

 

600 mg BID ATC

800 mg BID ATC

150 mg BID 3TC

W48 PP Population

n = 13

n = 14

n = 11

% <50 copies/mL

69.2

85.7

90.9

% <400 copies/mL

84.6

92.9

90.9

ΔCD4 cells/μL

261

277

200

% ≥1 log reduction in viral load

84.6

92.9

90.9

Safety Population

n = 17

n = 18

n = 16

No. severe AEs

10

13

17

No. SAEs

1

3

5

No. related AEs

3

6

5